Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
42 participants
INTERVENTIONAL
2024-11-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Design: A blinded, retrospective, randomized controlled trial. Setting: One-centred. Participants: Newborns who had intestinal surgery in the Ege University Faculty of Medicine Hospital Neonatal Surgery Intensive Care Unit and whose records can be accessed retrospectively from the electronic health records will be included. Those whose early enteral feeding initiation is contraindicated will not be included in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Early Enteral Feeding on Neonates After GIT Surgery
NCT04318353
Early Oral Feeding vs Traditional Post-operative Care In Emergency Abdominal Surgeries
NCT04431037
Feasibility and Efficacy of Enhanced Recovery After Surgery (ERAS) on Length of Stay Among Laparotomy Patients at Mbarara Regional Referral Hospital
NCT03665376
Influence of Early-feeding on Digestive Function of Patients After Esophageal Recontraction Surgery
NCT05892263
A Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy
NCT02415049
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design: A blinded, retrospective, randomized controlled trial. Setting: One-centred. Participants: Newborns who had intestinal surgery in the Ege University Faculty of Medicine Hospital Neonatal Surgery Intensive Care Unit and whose records can be accessed retrospectively from the electronic health records will be included. Those whose early enteral feeding initiation is contraindicated will not be included in the study.
Groups:
ERAS Group: Newborns who had breastmilk within the first 48 hours in the postoperative period will be in the ERAS group.
Control Group: Newborns who do not receive breast milk in the first 48 hours of the postoperative period will be in the control group.
Variables: The dependent variables of this study are the length of hospital stay, time until full feed (120 ml/kg/day), time until first oral feeding, time until first stool, body weight gain, feeding intolerance (abdominal distention and repeated vomiting-more than three times a day) and Accordion Severity Grading System of Surgical Complications Score. The independent variables of this research are the type of the surgery, enteral feeding time and the type of the nutrient.
Randomization: It was found that 80 newborns met the inclusion criteria for the control group. To randomly select 21 of these 80 newborns Random Integer Generator on www.random.org will be used. (https://www.random.org/integers/?num=21\&min=1\&max=80\&col=1\&base=10\&format=html\&rnd=new) It was found that 65 newborns met the inclusion criteria for the ERAS group. To randomly select 21 of these 65 newborns Random Integer Generator on www.random.org will be used (https://www.random.org/integers/?num=21\&min=1\&max=65\&col=1\&base=10\&format=html\&rnd=new). No stratification will be used in randomization.
Main Outcomes and Measures: The main outcomes of this study are LoS, time until full feed (120 ml/kg/day), time until first oral feeding, time until first stool, body weight gain, feeding intolerance (abdominal distention and vomiting). The secondary outcome is the Accordion Severity Grading System of Surgical Complications Score20.
Accordion Severity Grading System of Surgical Complications Score: It was developed by Strasberg in 2009. In this scoring, the frequency of complications is evaluated under the sub-headings of mild complications, moderate complications, severe complications requiring intervention with or without anaesthesia, organ system failure or death.
Statistics: The minimum sample size in each group was considered 21 and a total of 42 using a power formula with a = 0.05, power of 95%, and 0.50 effect size 1.06. To calculate the sample size G\*Power 3.1.9.2 programme was used. In determining the differences between the groups in terms of the main outcomes, the Mann-Whitney U or Chi-square tests will be used since they are independent groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CONTROL GROUP
Control Group: Electronic health records of the newborns who do not receive breast milk in the first 48 hours of the postoperative period will be in the control group.
No interventions assigned to this group
ERAS GROUP
ERAS Group: Electronic health records of the newborns who had breastmilk within the first 48 hours in the postoperative period will be in the ERAS group.
feeding with breastmilk within 48 hours after surgery
Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
feeding with breastmilk within 48 hours after surgery
Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* whose records can be accessed retrospectively from the electronic health records will be included.
Exclusion Criteria
1 Day
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Izmir Katip Celebi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ESRA ARDAHAN AKGUL
Assistant Professor, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esra ARDAHAN AKGÜL, Asst. Prof.
Role: STUDY_CHAIR
İzmir Katip Çelebi University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.